Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
uniQure B.V. (QURE)  
$4.56 0.19 (4%) as of 4:30 Wed 4/24


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 44,500,000
Market Cap: 202.92(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $4.7 - $22.2
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE™ silencing technology.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 53,265 53,265 74,223 229,905
Total Sell Value $339,844 $339,844 $555,147 $3,944,931
Total People Sold 3 3 4 13
Total Sell Transactions 3 3 5 43
End Date 2024-01-25 2023-10-24 2023-04-25 2022-04-25

   
Records found: 336
  Page 1 of 14  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Potts Jeannette Chief Legal Officer   •       –      –    2024-03-01 4 A $0.00 $0 D/D 49,500 96,600     -
   Abi-Saab Walid Chief Medical Officer   •       –      –    2024-03-01 4 A $0.00 $0 D/D 49,500 116,700     -
   Klemt Christian Chief Financial Officer   •       –      –    2024-03-01 4 A $0.00 $0 D/D 49,500 166,448     -
   Kapusta Matthew C CEO, Managing Director   •       •      –    2024-03-01 4 A $0.00 $0 D/D 150,000 590,839     -
   Caloz Pierre Chief Operating Officer   •       –      –    2024-03-01 4 A $0.00 $0 D/D 33,000 118,643     -
   Caloz Pierre Chief Operating Officer   •       –      –    2024-02-26 4 S $6.47 $61,174 D/D (9,455) 85,643 29%     
   Klemt Christian Chief Financial Officer   •       –      –    2024-02-26 4 S $6.38 $101,480 D/D (15,906) 116,948 29%     
   Kapusta Matthew C CEO, Managing Director   •       •      –    2024-02-26 4 S $6.35 $177,190 D/D (27,904) 440,839 29%     
   Abi-Saab Walid Chief Medical OfficerOfficer   •       –      –    2023-09-27 3 IO $0.00 $0 D/D 0 67,200 -14%     
   Dolmetsch Ricardo President, R&D   •       –      –    2023-09-18 4 S $7.46 $43,574 D/D (5,841) 163,404 21%     
   Caloz Pierre Chief Operating Officer   •       –      –    2023-07-10 4 AS $11.36 $171,729 D/D (15,117) 95,098 -43%     
   Potts Jeannette See Remarks   •       –      –    2023-06-13 4 A $0.00 $0 D/D 47,100 47,100     -
   Dolmetsch Ricardo President, R&D   •       –      –    2023-03-07 4 S $21.04 $17,610 D/D (837) 169,245 50%     
   Kapusta Matthew C CEO, Managing Director   •       •      –    2023-03-07 4 S $21.39 $53,924 D/D (2,521) 468,743 50%     
   Kuta Alexander Edward Iii Executive VP, Operations   •       –      –    2023-03-07 4 S $21.36 $12,496 D/D (585) 90,381 50%     
   Caloz Pierre Chief Operating Officer   •       –      –    2023-03-07 4 S $21.33 $21,117 D/D (990) 113,135 50%     
   Klemt Christian Chief Financial Officer   •       –      –    2023-03-07 4 S $21.36 $21,061 D/D (986) 134,441 50%     
   Kuta Alexander Edward Iii Executive VP, Operations   •       –      –    2023-02-28 4 S $21.04 $25,500 D/D (1,212) 90,966 45%     
   Gut Robert Director   –       •      –    2023-02-28 4 S $21.16 $30,280 D/D (1,431) 42,197 45%     
   Kapusta Matthew C CEO, Managing Director   •       •      –    2023-02-28 4 S $20.90 $104,939 D/D (5,021) 471,264 45%     
   Klemt Christian Chief Financial Officer   •       –      –    2023-02-28 4 S $20.90 $28,612 D/D (1,369) 135,427 45%     
   Jacques Rachelle Suzanne Director   –       •      –    2023-02-27 4 S $20.02 $7,688 D/D (384) 10,230 46%     
   Kuta Alexander Edward Iii Executive VP, Operations   •       –      –    2023-02-27 4 S $19.99 $110,225 D/D (5,514) 92,178 46%     
   Post Leonard E Director   –       •      –    2023-02-27 4 S $19.73 $7,675 D/D (389) 11,812 46%     
   Gut Robert Director   –       •      –    2023-02-27 4 S $19.79 $10,627 D/D (537) 43,628 46%     
  336 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 14
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us